Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visudyne in Recurrent High Grade EGFR-Mutated Glioblastoma
NCT04590664Phase 2Terminated
- Sponsor
- Emory University
- Start
- Jan 2021
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verteporfin in glioblastoma (GBM), sponsored by Emory University. Primary endpoints: Incidence of Adverse Events at 36 days, Maximum Tolerated Dose and 3 more. Started Jan 2021; status: terminated.
02
Drugs
verteporfin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04590664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590664.